Published in Neurology on April 25, 2006
Searching for a marker of REM sleep behavior disorder: submentalis muscle EMG amplitude analysis during sleep in patients with narcolepsy/cataplexy. Sleep (2008) 1.22
REM sleep behavior disorder and REM sleep without atonia as an early manifestation of degenerative neurological disease. Curr Neurol Neurosci Rep (2012) 1.19
Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med (2006) 1.10
The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease. Brain (2013) 1.02
Parasomnias: an updated review. Neurotherapeutics (2012) 0.98
REM sleep behaviour disorder in older individuals: epidemiology, pathophysiology and management. Drugs Aging (2010) 0.93
Morbidities in rapid eye movement sleep behavior disorder. Sleep Med (2013) 0.80
Lesional REM sleep behavior disorder localizes to the dorsomedial pons. Neurology (2014) 0.78
Treatment of sleeping disorders should be considered in clinical management of Parkinson's disease. Front Aging Neurosci (2014) 0.77
Rapid eye movement sleep behavior disorder in adults younger than 50 years of age. Sleep Med (2013) 0.76
A practical approach to the diagnosis and management of sleep disorders in patients with multiple sclerosis. Ther Adv Neurol Disord (2015) 0.75
From bench to bed: putative animal models of REM sleep behavior disorder (RBD). J Neural Transm (Vienna) (2013) 0.75
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20
The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology (2008) 5.94
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Mild cognitive impairment: ten years later. Arch Neurol (2009) 5.02
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain (2010) 4.77
Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56
Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage (2007) 4.41
An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36
Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain (2006) 4.07
Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2. Neurology (2013) 3.70
Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry (2010) 3.66
3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain (2007) 3.53
Chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiol Aging (2011) 3.27
Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol (2007) 3.25
Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One (2012) 3.11
Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain (2012) 3.08
Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet (2011) 2.76
Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology (2013) 2.73
[(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. Mayo Clin Proc (2013) 2.64
Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain (2007) 2.58
Brain β-amyloid load approaches a plateau. Neurology (2013) 2.50
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet (2008) 2.48
Assessing the temporal relationship between cognition and gait: slow gait predicts cognitive decline in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci (2012) 2.48
Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry (2008) 2.39
Risk factors for dementia with Lewy bodies: a case-control study. Neurology (2013) 2.38
Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol (2013) 2.29
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol (2007) 2.19
Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol (2002) 2.17
Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch Neurol (2006) 2.13
Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 2.12
Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol (2012) 2.09
Incidence of dementia among participants and nonparticipants in a longitudinal study of cognitive aging. Am J Epidemiol (2014) 2.09
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol (2008) 2.04
Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol (2013) 2.03
Physical exercise, aging, and mild cognitive impairment: a population-based study. Arch Neurol (2010) 2.02
Clinically undetected motor neuron disease in pathologically proven frontotemporal lobar degeneration with motor neuron disease. Arch Neurol (2006) 2.02
Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology (2012) 2.01
Prominent phenotypic variability associated with mutations in Progranulin. Neurobiol Aging (2007) 2.00
Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage (2008) 1.98
Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. AJNR Am J Neuroradiol (2003) 1.96
Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain (2009) 1.93
Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol (2008) 1.93
Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging (2006) 1.92
TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol (2014) 1.90
Rates of cerebral atrophy differ in different degenerative pathologies. Brain (2007) 1.90
Non-stationarity in the "resting brain's" modular architecture. PLoS One (2012) 1.90
Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc (2010) 1.85
Antemortem diagnosis of frontotemporal lobar degeneration. Ann Neurol (2005) 1.85
Patterns of atrophy differ among specific subtypes of mild cognitive impairment. Arch Neurol (2007) 1.84
TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener (2013) 1.83
Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain (2008) 1.82
Shining a light on posterior cortical atrophy. Alzheimers Dement (2012) 1.77
Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia. Mayo Clin Proc (2003) 1.73
Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment. Arch Neurol (2003) 1.73
Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies. Mov Disord (2011) 1.73
C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology (2013) 1.70
Rarity of encephalopathy associated with autoimmune thyroiditis: a case series from Mayo Clinic from 1950 to 1996. Thyroid (2002) 1.69
Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol (2013) 1.68
REM sleep behavior disorder: a possible early marker for synucleinopathies. Neurology (2006) 1.68
Imaging correlates of posterior cortical atrophy. Neurobiol Aging (2006) 1.65
Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol (2010) 1.60
Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet (2011) 1.60
A preliminary fluorodeoxyglucose positron emission tomography study in healthy adults reporting dream-enactment behavior. Sleep (2006) 1.54
Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol (2008) 1.53
Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol (2006) 1.50
Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study. Ann Neurol (2012) 1.49
Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion. Neurology (2012) 1.49
Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49
TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol (2014) 1.47
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Rapidly progressive neurodegenerative dementias. Arch Neurol (2009) 1.46
Temporoparietal atrophy: a marker of AD pathology independent of clinical diagnosis. Neurobiol Aging (2009) 1.46
Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol (2008) 1.45
Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol (2012) 1.44
Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain (2006) 1.43
Association of prior stroke with cognitive function and cognitive impairment: a population-based study. Arch Neurol (2009) 1.40
Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging (2011) 1.40
Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations. Arch Neurol (2007) 1.39
Antemortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging (2010) 1.37
Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol (2002) 1.36
Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer's disease. Clin Neuropsychol (2006) 1.35
Atypical progressive supranuclear palsy with corticospinal tract degeneration. J Neuropathol Exp Neurol (2006) 1.34
C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. JAMA Neurol (2013) 1.34
Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. Mov Disord (2009) 1.30
Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiol Aging (2012) 1.30
The "eye-of-the-tiger" sign is not pathognomonic of the PANK2 mutation. Arch Neurol (2006) 1.28
Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging (2006) 1.28
Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann Neurol (2012) 1.28
Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol (2010) 1.28
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol (2009) 1.27
Survival profiles of patients with frontotemporal dementia and motor neuron disease. Arch Neurol (2009) 1.26
Vascular dementia in a population-based autopsy study. Arch Neurol (2003) 1.25
Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology (2008) 1.24